SCHEMBL7513699

SCHEMBL7513699

CN(C(=O)c1nn(C)cc1N)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 4/20 0.42
HPGD P15428 3/20 0.42
POLB P06746 1/20 0.41
ALDH1A1 P00352 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
CNR1 P21554 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7517927 0.99 PDE10A (0.44) PDE10ASMN1; SMN2TSHRHPGDPOLB
SCHEMBL7510001 0.93 PDE10A (0.42) PDE10ASMN1; SMN2TSHRALDH1A1CNR1
SCHEMBL7513697 0.84 PDE10A (0.43) PDE10ASMN1; SMN2TSHRHPGDPOLB
SCHEMBL7517923 0.82 PDE10A (0.43) PDE10ASMN1; SMN2TSHRHPGDPOLB
SCHEMBL1559840 0.77 MAP4K1 (0.40) PDE10ASMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL7509997 0.76 PDE10A (0.41) PDE10ASMN1; SMN2TSHRHPGDALDH1A1
SCHEMBL4289358 0.75 RAB9A (0.41) TSHRHPGDPOLBALDH1A1NPC1
SCHEMBL7517978 0.73 SMN1; SMN2 (0.71) PDE10ASMN1; SMN2TSHRHPGDALDH1A1
SCHEMBL7523227 0.72 PDE10A (0.39) PDE10ASMN1; SMN2TSHRALDH1A1RAB9A
SCHEMBL4279828 0.71 LMNA (0.70) PDE10ASMN1; SMN2TSHRHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP claimed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US claimed
US-8623866-B2 2014-01-07 US claimed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP claimed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO claimed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US claimed
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A PDE10A 1/4885SMN1; SMN2 1370/4885TSHR 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.